SNN vs ZBH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ZBH is the larger of the two ($19.27B market cap): the incumbent the market prices for continued execution (11.36x forward earnings, beta 0.47). SNN is the smaller challenger ($12.55B), priced similarly on forward earnings (12.66x): more room to run, but more to prove. If the story you believe is SNN's (Sports Medicine is doing the compounding), SNN is the more direct way to own it; if it is ZBH's (Hips and technology are carrying the growth, not knees), ZBH is.

SNN vs ZBH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricSNNZBHWhat it tells you
Market cap$12.55B$19.27BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.6611.36Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E20.4325.71Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.670.47Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range36% of range68% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book12.331.52How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how SNN and ZBH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SNN and ZBH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SNN and ZBH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Smith & Nephew (SNN) do?

Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Orthopaedics, the largest at $2,437 million of 2025 revenue, covers knee implants, hip implants, other reconstruction and a trauma and extremities line. Sports Medicine & ENT, $1,934 million in 2025, sells arthroscopic repair systems, the REGENETEN bioinductive implant for rotator cuff repair, visualisation and resection hardware, and ear, nose and throat instruments. Advanced Wound Management, $1,793 million, spans foam and antimicrobial dressings, negative pressure wound therapy devices such as PICO and RENASYS, and a bioactives portfolio that includes SANTYL and skin substitutes. Group revenue was $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and the business employs roughly 17,000 people. Around half of sales come from the United States: US revenue was $1,591 million of the $3,097 million booked in the first half of 2026. Emerging markets, where the company grew 10.6% underlying in that half, are the fastest-moving geography and also the source of the China pricing risk described below. The customer is a hospital or a surgical centre, the sale is usually a consumable or an implant rather than a capital item, and revenue is therefore closely tied to elective procedure volumes in the United States, Europe and Japan.

Full SNN guide

What does Zimmer Biomet (ZBH) do?

Zimmer Biomet Holdings, based in Warsaw, Indiana, makes the hardware that goes inside roughly a million joint replacement patients a year. Its reporting lines are knees, hips, S.E.T. (sports medicine, extremities and trauma), and craniomaxillofacial and thoracic, with a separate technology and data line covering the ROSA robotic platform, navigation and mixed-reality software. Trailing twelve-month revenue runs about ~$8.57B across roughly 17,000 employees. Two acquisitions reshaped the mix recently: Paragon 28 for about ~$1.2B, which added a dedicated foot and ankle franchise, and Monogram Technologies for about ~$177M in equity value (~$4.04 per share, closed in 2025), which brought semi-autonomous and autonomous robotic capability alongside the existing ROSA installed base of nearly 2,000 systems.

Full ZBH guide

SNN vs ZBH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • SNN drivers: Sports Medicine is doing the compounding; Orthopaedics margin ahead of Orthopaedics revenue.
  • ZBH drivers: Hips and technology are carrying the growth, not knees; ROSA is a placement business, not a robot business.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The clearest risk is that US Orthopaedics does not turn. For ZBH, the most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of the August 2026 update that remained an investigation notice, with no securities complaint on file).

SNN or ZBH: which should you pick?

With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate SNN from ZBH. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SNN and ZBH guides.

SNN vs ZBH: the full fundamentals

SNN. The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table more than in any accounting subtlety: the largest franchise earns the lowest margin and grows slowest. At ~13 times forward consensus earnings in November 2026, after two guidance cuts and the end of talks with Johnson & Johnson, investors are paying for the RISE targets to close that gap, or for the Orthopaedics strategic review to force the issue on portfolio structure. Five covering analysts carry a mean target of ~$33.19 and a hold rating.

ZBH. At a market capitalization near ~$19.3B, Zimmer Biomet is valued at roughly 2.25x trailing sales and about ~11.4x forward adjusted earnings, against a GAAP trailing P/E near ~26x that is weighed down by amortization and deal costs. In August 2026 Stryker traded near ~20.6x forward earnings and Johnson & Johnson near ~23.5x, so the gap is close to half. What the multiple is arguing about is durability of growth: cash generation is strong, with ~$1.3B to ~$1.4B of 2026 free cash flow expected, but organic growth sits in the low single digits; the 21 analysts tracked by Yahoo carry a mean target near ~$117, and Leerink raised its target to $112 from $110 in November.

Headline figures (approximate, November 2026): SNN shows revenue (ttm) ~$6.30 billion for the twelve months to June 27, 2026 (the latest period with full financial statements), against $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and $5,810 million in 2024. First-half 2026 growth was 4.6% reported but only 2.3% underlying. Third-quarter 2026 revenue was ~$1.55 billion, up 3.4% on both underlying and reported bases. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved., earnings and adjusted earnings Attributable profit of ~$635 million on a trailing basis, giving roughly $1.47 per ADS at the two-for-one ratio (~73-74 cents per ordinary share). Full-year 2025 EPS was 72.1 cents per ordinary share on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin), with adjusted EPS of 102.0 cents per ordinary share, about $2.04 per ADS. 2026 trading profit guidance is now ~$1.25 billion. The gap between operating and trading profit, roughly $440 million in 2025, is restructuring, acquisition amortisation and legal items., franchise growth and margins 2025 segment trading margins were 14.9% for Orthopaedics, 23.8% for Sports Medicine & ENT and 24.9% for Advanced Wound Management. Third-quarter 2026 underlying growth was Orthopaedics +2.5%, Sports Medicine & ENT +7.9% (joint repair +11.2%) and Advanced Wound Management -0.2% (Bioactives -8.8%). By geography, the US grew 3%, other established markets 3.2% and emerging markets 4.8%., cash flow and balance sheet Free cash flow of ~$1.06 billion on Yahoo Finance's trailing basis and $836 million in 2025; 2026 guidance is now ~$750 million, down from ~$800 million. Total debt is ~$3.78 billion against ~$754 million of cash, and adjusted net debt to EBITDA was 1.8 times at the half. $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027.; ZBH shows revenue (ttm) ~$8.57B (Q3 2026 up ~3.1% year over year), q3 2026 results Net sales ~$2.06B; adjusted EPS ~$1.90 vs ~$1.88 expected, margins (ttm) ~69% gross, ~17% GAAP operating, ~9% net, net income (ttm) ~$767M GAAP.

The bottom line: SNN vs ZBH

SNN and ZBH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined SNN and ZBH exposure against your real portfolio. It is not an investment adviser.

Wondering how SNN or ZBH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Smith & Nephew

Ask Walnut's AI anything about SNN and see how it fits what you own.

FAQ

What is the difference between SNN and ZBH?

+

Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Zimmer Biomet Holdings, based in Warsaw, Indiana, makes the hardware that goes inside roughly a million joint replacement patients a year. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is SNN or ZBH the better stock?

+

Neither is universally better. ZBH is the larger incumbent; SNN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, SNN or ZBH?

+

On forward P/E (as of November 2026), SNN trades at 12.66x and ZBH at 11.36x, so ZBH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both SNN and ZBH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of SNN vs ZBH?

+

SNN: The clearest risk is that US Orthopaedics does not turn. Knee implants fell 7.2% in the US in the second quarter of 2026, US hips and knees were still weak in the third, and the fix depends on launches, principally LANDMARK and wider LEGION MS set deployment, that mostly land in 2027. Launches slip, surgeons switch slowly, and a competitor with four times the revenue can out-spend the response. Advanced Wound Bioactives is the second pressure point: revenue fell 8.1% underlying in the first half and 8.8% in the third quarter after the January 2026 US reimbursement reset on skin substitutes, and the full-year headwind is now expected toward the upper end of a $20 million to $40 million range. China is a third. Volume-based procurement has already compressed sports medicine pricing, the ENT tender process has been delayed into the second half of 2026, and the company has been running down channel inventory ahead of it, so the reported growth in that market is not a clean read on demand. Execution risk sits on top of all of it: the company has now cut 2026 guidance twice, in August and November, and the second cut reached trading profit, free cash flow and ROIC as well as revenue. The strategic review of Orthopaedics adds uncertainty in both directions, since the Johnson & Johnson talks ended without a deal. RBC cut its price target to GBP 11.50 from GBP 12.50 in November. There is a governance gap as well. CFO John Rogers resigned on August 19, 2026 and left on September 30; Pierre Palassian is interim CFO while the search continues. Cevian's 14.2% position could force portfolio action or leave a large overhang if the thesis is abandoned. Legacy metal-on-metal hip claims still carry provisions, adjusted net debt to EBITDA was 1.8 times at the half, and $350 million of corporate bonds plus $140 million of private placement debt fall due in the first half of 2027. ZBH: The most concrete overhang is credibility: the November 5, 2025 guidance pivot cut the price roughly 15% in a day, and in January 2026 Hagens Berman announced an investigation into whether management misled investors about international stability (as of the August 2026 update that remained an investigation notice, with no securities complaint on file). Margin direction is the second issue, since adjusted operating margin fell ~210 basis points year over year to ~25.7% in the second quarter, the company guides to a slight full-year decline, and management itself called its ~46.5% operating expense profile not sustainable. China is small at roughly 2% of revenue and 1% of EBITDA but was down about 20% this year under volume-based procurement tenders (about a 50 basis point drag on 2026 growth), and VBP-style pricing pressure has a habit of spreading to other categories. Tariffs cut both ways here: a favorable ~$30M adjustment for probable US refunds helped first-half 2026 profit and does not repeat, and the company's largely domestic manufacturing base limits but does not eliminate exposure. Longer term, competitive pressure from Stryker's Mako franchise and the unresolved argument over whether GLP-1 weight-loss drugs shrink or expand the eligible joint replacement population both sit outside management's control. Knees, the largest franchise, were roughly flat in the third quarter with US knees down ~2%, and the Monogram launch depends on FDA clearance; analysts expect only ~4.8% adjusted EPS growth in 2027.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell SNN or ZBH; figures are approximate and dated (as of November 2026). Verify current data before investing.